Andrew M. Kaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew M. Kaz has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- William M. Grady
Fred Hutchinson Cancer Center, Seattle, Washington
5 shared publications Chao-Jen Wong
3 shared publicationsYanxin Luo
Division of Clinical Research; Fred Hutchinson Cancer Research Center; Seattle, WA USA; Department of Colorectal Surgery; the Sixth Affiliated Hospital; Sun Yat-Sen University; Guangzhou, PR China; Gastrointestinal Institute; Sun Yat-Sen University; Guangzhou, PR China
3 shared publicationsAmitabh Chak
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
2 shared publicationsJoseph E. Willis
Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH
2 shared publications- Rom S. Leidner
EACRI, Providence Cancer Institute, Portland, Oregon, USA
2 shared publications
Latest Publications
- 23 June 2016
- Published by Springer Nature in Tumor Biology
- Vol. 37 (9) , 12477-12483
Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation
Beta-tropomyosin (β-tropomyosin, TPM2) has been found to be downregulated in colorectal cancer (CRC) in previous studies. In this study, we aimed to investigate the mechanisms and potential biological consequences of the downregulation of TPM2 in colorectal cancer. TPM2 expression in colorectal cancer was assessed by qRT-PCR and immunostaining. The biological functions of TPM2 were assessed in cell lines either overexpressing or underexpressingTPM2. Aberrant DNA methylation in the promoter region is associated with suppression of TPM2 expression in primary colorectal cancer tissue samples. Treatment with the demethylation agent 5-AZA can induceTPM2 expression in colorectal cancer cell lines. Reconstitution of TPM2 suppresses cell proliferation and migration in colorectal cancer cell lines, whereas the loss of TPM2 expression is associated with increased tumor proliferation and migration in vitro, which was accompanied by RhoA activation. In summary, our findings indicate that TPM2 appears to be commonly silenced by aberrant DNA methylation in colon cancer. TPM2 loss is associated with RhoA activation and tumor proliferation.
- 23 June 2016
- Published by Springer Nature in Tumor Biology
- Vol. 37 (9) , 12477-12483
Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation
Beta-tropomyosin (β-tropomyosin, TPM2) has been found to be downregulated in colorectal cancer (CRC) in previous studies. In this study, we aimed to investigate the mechanisms and potential biological consequences of the downregulation of TPM2 in colorectal cancer. TPM2 expression in colorectal cancer was assessed by qRT-PCR and immunostaining. The biological functions of TPM2 were assessed in cell lines either overexpressing or underexpressingTPM2. Aberrant DNA methylation in the promoter region is associated with suppression of TPM2 expression in primary colorectal cancer tissue samples. Treatment with the demethylation agent 5-AZA can induceTPM2 expression in colorectal cancer cell lines. Reconstitution of TPM2 suppresses cell proliferation and migration in colorectal cancer cell lines, whereas the loss of TPM2 expression is associated with increased tumor proliferation and migration in vitro, which was accompanied by RhoA activation. In summary, our findings indicate that TPM2 appears to be commonly silenced by aberrant DNA methylation in colon cancer. TPM2 loss is associated with RhoA activation and tumor proliferation.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S856
Tu1181 Global DNA Methylation Patterns in Barrett's Esophagus, Dysplastic Barrett's, and Esophageal Adenocarcinoma Are Associated With BMI, Gender, and Tobacco Use
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S856
Tu1181 Global DNA Methylation Patterns in Barrett's Esophagus, Dysplastic Barrett's, and Esophageal Adenocarcinoma Are Associated With BMI, Gender, and Tobacco Use
- 10 January 2014
- Published by Taylor & Francis in Epigenetics
- Vol. 9 (4) , 492-502
Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age
Alterations in DNA methylation have been proposed to create a field cancerization state in the colon, where molecular alterations that predispose cells to transformation occur in histologically normal tissue. However, our understanding of the role of DNA methylation in field cancerization is limited by an incomplete characterization of the methylation state of the normal colon. In order to determine the colon's normal methylation state, we extracted DNA from normal colon biopsies from the rectum, sigmoid, transverse, and ascending colon and assessed the methylation status of the DNA by pyrosequencing candidate loci as well as with HumanMethylation450 arrays. We found that methylation levels of repetitive elements LINE-1 and SAT-α showed minimal variability throughout the colon in contrast to other loci. Promoter methylation of EVL was highest in the rectum and progressively lower in the proximal segments, whereas ESR1 methylation was higher in older individuals. Genome-wide methylation analysis of normal DNA revealed 8388, 82, and 93 differentially methylated loci that distinguished right from left colon, males from females, and older vs. younger individuals, respectively. Although variability in methylation between biopsies and among different colon segments was minimal for repetitive elements, analyses of specific cancer-related genes as well as a genome-wide methylation analysis demonstrated differential methylation based on colon location, individual age, and gender. These studies advance our knowledge regarding the variation of DNA methylation in the normal colon, a prerequisite for future studies aimed at understanding methylation differences indicative of a colon field effect.
- 10 January 2014
- Published by Taylor & Francis in Epigenetics
- Vol. 9 (4) , 492-502
Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age
Alterations in DNA methylation have been proposed to create a field cancerization state in the colon, where molecular alterations that predispose cells to transformation occur in histologically normal tissue. However, our understanding of the role of DNA methylation in field cancerization is limited by an incomplete characterization of the methylation state of the normal colon. In order to determine the colon's normal methylation state, we extracted DNA from normal colon biopsies from the rectum, sigmoid, transverse, and ascending colon and assessed the methylation status of the DNA by pyrosequencing candidate loci as well as with HumanMethylation450 arrays. We found that methylation levels of repetitive elements LINE-1 and SAT-α showed minimal variability throughout the colon in contrast to other loci. Promoter methylation of EVL was highest in the rectum and progressively lower in the proximal segments, whereas ESR1 methylation was higher in older individuals. Genome-wide methylation analysis of normal DNA revealed 8388, 82, and 93 differentially methylated loci that distinguished right from left colon, males from females, and older vs. younger individuals, respectively. Although variability in methylation between biopsies and among different colon segments was minimal for repetitive elements, analyses of specific cancer-related genes as well as a genome-wide methylation analysis demonstrated differential methylation based on colon location, individual age, and gender. These studies advance our knowledge regarding the variation of DNA methylation in the normal colon, a prerequisite for future studies aimed at understanding methylation differences indicative of a colon field effect.
- 1 January 2014
- Published by Elsevier in Cancer Letters
- Vol. 342 (2) , 193-199
Epigenetic biomarkers in esophageal cancer
- 1 January 2014
- Published by Elsevier in Cancer Letters
- Vol. 342 (2) , 193-199
Epigenetic biomarkers in esophageal cancer
- 14 December 2011
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 51 (4) , 384-393
Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma
The aberrant DNA methylation of tumor suppressor genes occurs frequently in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) and likely affects the initiation and progression of BE to EAC. In the present study, we discovered PKP1 as a novel methylated gene in EAC and then investigated the role of loss of PKP1, a constituent of the desmosome complex found in stratified epithelial layers, on the behavior of Barrett's esophagus and esophageal adenocarcinoma cells. By using primary esophageal tissue samples we determined that PKP1 was rarely methylated in normal squamous esophagus (5/55; 9.1%) and BE (5/39; 12.8%) and more frequently methylated in Barrett's esophagus with high‐grade dysplasia (HGD) or EAC (20/60; 33.3%; P < 0.05). Furthermore, PKP1 levels were decreased in BE and HGD/EAC cases compared to normal squamous esophagus cases. Knockdown of PKP1 in the BE cell lines CP‐A and CP‐D (both normally express PKP1) resulted in increased cell motility. Thus, PKP1 loss secondary to promoter methylation, as well as other mechanisms, may promote the progression of BE to EAC in a subset of patients via decreased desmosome assembly and increased cell motility.
- 14 December 2011
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 51 (4) , 384-393
Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma
The aberrant DNA methylation of tumor suppressor genes occurs frequently in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) and likely affects the initiation and progression of BE to EAC. In the present study, we discovered PKP1 as a novel methylated gene in EAC and then investigated the role of loss of PKP1, a constituent of the desmosome complex found in stratified epithelial layers, on the behavior of Barrett's esophagus and esophageal adenocarcinoma cells. By using primary esophageal tissue samples we determined that PKP1 was rarely methylated in normal squamous esophagus (5/55; 9.1%) and BE (5/39; 12.8%) and more frequently methylated in Barrett's esophagus with high‐grade dysplasia (HGD) or EAC (20/60; 33.3%; P < 0.05). Furthermore, PKP1 levels were decreased in BE and HGD/EAC cases compared to normal squamous esophagus cases. Knockdown of PKP1 in the BE cell lines CP‐A and CP‐D (both normally express PKP1) resulted in increased cell motility. Thus, PKP1 loss secondary to promoter methylation, as well as other mechanisms, may promote the progression of BE to EAC in a subset of patients via decreased desmosome assembly and increased cell motility.
- 1 December 2011
- Published by Taylor & Francis in Epigenetics
- Vol. 6 (12) , 1403-1412
DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses
Barrett’s esophagus (BE) is a metaplastic process whereby the normal stratified, squamous esophageal epithelium is replaced by specialized intestinal epithelium. Barrett’s is the only accepted prec...
- 1 December 2011
- Published by Taylor & Francis in Epigenetics
- Vol. 6 (12) , 1403-1412
DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses
Barrett’s esophagus (BE) is a metaplastic process whereby the normal stratified, squamous esophageal epithelium is replaced by specialized intestinal epithelium. Barrett’s is the only accepted prec...